Beijing, China, November 14, 2025 — On this World Diabetes Day, Gan & Lee Pharmaceuticals. (stock code: 603087.SH, hereinafter referred to as “Gan & Lee”) joined hands with its overseas subsidiaries and global partners to actively respond to the core theme of "Diabetes & Well-being" proposed by the International Diabetes Federation (IDF). We have launched an online and offline health public welfare initiative that transcends borders, raising awareness about the diabetic community. We believe that true happiness begins with the protection of health and is also derived from every sincere companionship and understanding.

In Beijing, we have established six interactive zones designed to guide participants through every step of health management—from building awareness to applying knowledge, and finally to daily reinforcement. This experiential approach transforms professional diabetes knowledge from abstract concepts into tangible, warm guidance that can be seen and felt.

Using an "interactive challenge" format, the event turned key knowledge into engaging experiences. Participants simulated challenges like "weighted hopscotch," feeling the physical impact of diabetes firsthand. This hands-on learning, supported by our staff, helped them master practical skills and debunk common myths, such as "Diabetes cannot be prevented" Now, knowledge is no longer dry theory, but actionable life guidance. 

At the same time, Gan & Lee collaborated with its overseas teams and global partners to launch the "Office Fitness Hit-up" campaign, promoting workplace health through offline fitness activities and an online cross-time-zone social media challenge. Participants worldwide united under the shared belief: "Beat Sugar at Work, Start Now."

From fun community science-based activities in China to health public welfare advocacy in overseas workplaces; from employees' health initiatives in subsidiaries to global cooperation online, Gan & Lee continues to leverage "international expansion + public welfare implementation" as dual wings. Striving to build a “universal participation, global cooperation” ecosystem for diabetes prevention and treatment.

Looking ahead, as Gan & Lee continues to advance in innovative drug R&D and deepen its presence in overseas markets, we will remain steadfast in protecting global public health with our specialized expertise. We are committed to collaborating with partners worldwide to transcend geographical boundaries through care, integrate hope into everyday life, and imbue the global fight against diabetes with the distinctive warmth of Gan & Lee.

About Gan & Lee

Gan & Lee Pharmaceuticals developed the first Chinese domestic insulin analog. Currently, Gan & Lee has six core insulin products, including five insulin analog varieties: long-acting glargine injection (Basalin^®), fast-acting lispro injection (Prandilin™), fast-acting aspart injection (Rapilin^®), mixed protamine zinc lispro injection (25R) (Prandilin™25), aspart 30 injection (Rapilin^®30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin^®30). The company has two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine^®).

In China's 2024 National Insulin-Specific Centralized Procurement, Gan & Lee Pharmaceuticals ranked  first among all selected companies in terms of procurement demand for insulin analogs. The company is also making strides in international markets, with the disposable pen needle (GanleeFine^®) approved by the US Food and Drug Administration (FDA) in 2020 and received GMP inspection approval from the European Medicines Agency (EMA) in 2024. These achievements significantly boost Gan & Lee’s competitiveness in both international and domestic markets.

In the future, Gan & Lee will strive for comprehensive coverage in diabetes treatment. Moving forward with its mission to become a world-class pharmaceutical company, Gan & Lee will also actively develop new chemical entities and biological drugs, focusing on treatments for metabolic diseases, cardiovascular diseases, and other therapeutic areas.